Allergy Therapeutics plc Stock

Equities

AGY

GB00B02LCQ05

Biotechnology & Medical Research

Market Closed - London S.E. 11:35:28 2024-06-10 am EDT 5-day change 1st Jan Change
6 GBX +14.29% Intraday chart for Allergy Therapeutics plc +37.14% +140.00%
Sales 2022 72.77M 92.43M Sales 2023 59.59M 75.69M Capitalization 7.13M 9.06M
Net income 2022 -13M -16.51M Net income 2023 -43M -54.62M EV / Sales 2022 1.7 x
Net cash position 2022 9.99M 12.68M Net Debt 2023 21.14M 26.86M EV / Sales 2023 0.47 x
P/E ratio 2022
-9.69 x
P/E ratio 2023
-0.16 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 6.79%
More Fundamentals * Assessed data
Dynamic Chart
AIM WINNERS & LOSERS: Arecor Therapeutics dives on funding needs AN
Allergy Therapeutics welcomes peanut allergy vaccine trial results AN
Abingdon Health buys IVDeology Holdings AN
Allergy Therapeutics plc Provides Further Details from Positive Top Line Results from G306 Phase III Field Study G306 to Evaluate the Efficacy and Safety of Grass MATA MPL CI
Allergy Therapeutics Announces Resignation of Mary Tavener as Non-Executive Director CI
EARNINGS AND TRADING: Solid State ups outlook; Quartix trading in line AN
Allergy Therapeutics Gets OK to Draw Down GBP15 Million From Amended Loan Facility MT
AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue AN
Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Reports Fiscal H1 Revenue GBP33.6M MT
Earnings Flash (AGY.L) ALLERGY THERAPEUTICS Posts Fiscal H1 Loss GBX-0.58 MT
Allergy Therapeutics plc Provides Sales Guidance for the Second Half and Full Year Ending on 30 June 2024 CI
Allergy Therapeutics plc Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Allergy Therapeutics starts dosing patients in peanut allergy trial AN
Allergy Therapeutics Announces Commencement of Subcutaneous Dosing of Peanut Allergic Patients in the Phase I/IIa PROTECT Trial Evaluating its Novel Virus-Like Particle Based Peanut Allergy Vaccine Candidate CI
Allergy Therapeutics plc Announces Appointment of Shaun Furlong to Board of Directors CI
More news
1 day+10.42%
1 week+32.50%
Current month+43.14%
1 month+84.03%
3 months+122.96%
6 months+189.85%
Current year+131.88%
More quotes
1 week
4.25
Extreme 4.25
5.84
1 month
3.00
Extreme 3
5.84
Current year
1.80
Extreme 1.8
5.84
1 year
0.80
Extreme 0.8
5.84
3 years
0.80
Extreme 0.8
40.50
5 years
0.80
Extreme 0.8
40.50
10 years
0.80
Extreme 0.8
40.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 09-06-30
Director of Finance/CFO - 22-03-31
Chief Tech/Sci/R&D Officer - 03-12-31
Members of the board TitleAgeSince
Director/Board Member 67 17-06-05
Chairman 73 10-09-30
Director/Board Member - 22-12-05
More insiders
Date Price Change Volume
24-06-10 6 +14.29% 4 648 143
24-06-07 5.25 0.00% 86,598
24-06-06 5.25 +0.96% 1,816,018
24-06-05 5.2 +4.00% 2,751,957
24-06-04 5 +14.29% 1,565,971

Delayed Quote London S.E., June 10, 2024 at 04:48 am EDT

More quotes
Allergy Therapeutics plc is a United Kingdom-based integrated specialty pharmaceutical company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.
More about the company